We’re thrilled to announce that we have secured new funding to advance our innovative therapy for hair loss! In September, we have secured a first tranche of approximately €2 million, with plans for a second closing next year.
These new funds will go towards the production of our treatment candidate sCD83, which will bring us closer to finally start treating patients who are suffering from hair loss. With our topical treatment, we aim to treat hormonal and immune-related hair loss and address the big impact hair loss can have on patients.
Plattform Life Sciences recently featured our therapy based on the soluble version of CD83 in a case study. Read the full article (in German) to learn more about our therapy that’s tackling hair loss at its root.
